Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Prevention and risk

Topic: Risk, prevention and care in population studies

Plain-language summary

Background APOE ε4 carriers have increased Alzheimer's disease risk and altered omega-3 metabolism. No large-scale prevention trials have tested high-dose docosahexaenoic acid (DHA) supplementation specifically in non-demented APOE ε4 carriers with low baseline omega-3 intake for early intervention. Methods We conducted a phase IIa 24-month, randomised, double-blind, placebo-controlled trial (NCT03613844) at the University of Southern California between September 2018 and May 2024. Participants aged 55-80 years without dementia, low dietary DHA intake ( Findings Of 739 screened individuals, 365 participants were randomised (181 LP arm, 184 no-LP arm). Mean age was 66.4 years (SD 5.7), 210 (58%) were female, 142 (39%) were Hispanic, 173 (47%) were APOE ε4 carriers. DHA supplementation increased CSF DHA/AA ratio at 6 months vs placebo (0.17 [95% CI 0.15-0.18] vs -0.02 [95% CI -0.04 to -0.0004]; difference 0.19 [95% CI 0.16-0.21]; p Interpretation High-dose DHA achieved CNS target engagement in non-demented older adults with low baseline omega-3 intake, independent of APOE ε4. Despite biochemical target engagement, no differences in cognition or brain structure were observed over 24 months. Future research should prioritise brain DHA metabolism over further supplementation trials. Funding National Institute on Aging (R01AG057684) and the ADDF (GC-201711-2014197).

What this study adds

Evidence grade: Null result

The record lists 365 participants. High-dose DHA supplements raised DHA levels in the spinal fluid of older adults without dementia, showing the supplement reached the brain. Its stated limit: Single-centre phase IIa trial whose primary endpoint was a biochemical target-engagement measure, not cognition; high dropout; two years may be too short to detect a prevention effect.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Yassine, H. N., Pour, S. G., Juarez, M., Arrelanas, I. C., Ali, N., Dikeman, D., et al. (2026). CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial. EBioMedicine. https://doi.org/10.1016/j.ebiom.2026.106316

Vancouver

Yassine HN, Pour SG, Juarez M, Arrelanas IC, Ali N, Dikeman D, et al. CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial. EBioMedicine. 2026. doi:10.1016/j.ebiom.2026.106316. PMID: 42315445.

BibTeX

@article{yassine2026-42315445,
  author  = {Yassine, Hussein N and Pour, Sara Ghasem and Juarez, Marlene and Arrelanas, Isabella C and Ali, Nada and Dikeman, Dante and Sanchez, Ashley and Park, Jackson and others},
  title   = {{CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial}},
  journal = {EBioMedicine},
  year    = {2026},
  doi     = {10.1016/j.ebiom.2026.106316},
  pmid    = {42315445},
  url     = {https://doi.org/10.1016/j.ebiom.2026.106316}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

High-dose DHA supplements raised DHA levels in the spinal fluid of older adults without dementia, showing the supplement reached the brain. However, over 24 months there were no differences in cognition or brain structure, so this supplement did not affect these outcomes in this trial.

Study details

Limitations

Single-centre phase IIa trial whose primary endpoint was a biochemical target-engagement measure, not cognition; high dropout; two years may be too short to detect a prevention effect.

How this study scored 60/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 8 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 2 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 59 of the 98 points it could be judged on, which is 60 of 100. Total 60 of 100.59 of the 98 points we could judge = 60 of 100

Published in a peer-reviewed journal, and it is a mid-stage phase 2 trial. We have no data on free to read, so that was left out: it earned 59 of the 98 points we could judge it on, which is 60 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (EBioMedicine)
Journal's citation record 2 / 4 EBioMedicine: journal h-index 181 (OpenAlex, 2026-10-29)
Study design 8 / 12 A mid-stage phase 2 trial
Strength of evidence 3 / 5 Rated “null-result” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 2 / 4 365 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 1 / 7 Cited 4 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.0 citations a year over 2 year(s) since 2026
Impact for its field and year 4 / 6 Cited 17.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Lon S. Schneider: h-index 73 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Southern California: institution h-index 1,521 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42315445)
Free to read — / 2 Access not recorded — left out of this score
Points 59 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 59 of the 98 points we could judge it on is 60 out of 100.
Total 60 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

In the news

2 news articles on alzhub's news page cite this paper.

Related studies in Prevention and risk from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →